Clinical trial · Observational
Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa
Comparison of Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients Colonized Patients Between Chronic and Non-chronic Patients Colonized With Pseudomonas Aeruginosa
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): only one patient was included
Summary
Brief summary (as posted)
Rates of DMBT1 (Glycoprotein like) in Sputum of CF Patients with or without may be different according to their Pseudomonas Aeruginosa chronic colonization status. The aim of this study is to compare rates of DMBT1 (Glycoprotein like) in Sputum of CF patients with or without a Pseudomonas Aeruginosa chronic colonization.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Brain Tumor | Malignant Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- group 1
- description
- CF patients with Pseudomonas aeruginosa chronic colonization.
- label
- group 2
- description
- CF patients without a Pseudomonas aeruginosa chronic colonization.
Primary outcomes (1)
- measure
- measure glycoprotein-like DMBT1 by Elisa
- timeFrame
- at 1 months
- description
- DMBT1 in mg DMBT1 / mg of total protein measured by BCA (BiCinchoninic acid Assay) present in each sputum
Secondary outcomes (1)
- measure
- measure MUC5B by Elisa
- timeFrame
- at 1 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
Show eligibility criteria text
Inclusion Criteria: * CF patient 6 years * Availability of sputum * Signed Informed consent Exclusion Criteria: * Cardiac insufficiency * Anti-inflammatory drugs on going * Oral corticosteroid therapy * Inhaled corticosteroids during the two weeks before inclusion, * Patient awaiting lung transplantation * Patient with a past history of heart/lung transplantation * Patient with a sputum examination positive for : atypical mycobacteria, Burkholderia cepacia, Stenotrophomonas maltophilia, * Patient chronically colonized with multiresistant Pseudomonas aeruginosa * Orkambi© or Kalydeco© therapy * Change of the CF treatment during the last 4 weeks +/- 2 days before inclusion : corticosteroid, pancreatic extracts, antisecretory drugs...
References
Publications (0)
Data not yet available